NCT03244956 2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
Clinical Trials
12 trialsNCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT02145143 2025-06-18
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT06431620 2024-05-28
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer
Nanjing First Hospital, Nanjing Medical University
Phase NA Recruiting
NCT06405217 2024-05-08
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Nanjing First Hospital, Nanjing Medical University
Phase NA Recruiting
NCT00415233 2023-12-19
HiLo
University College, London
Phase 3 Unknown
NCT01837745 2023-05-17
ESTIMABL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Active not recruiting
NCT02278198 2019-10-24
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
University of Colorado, Denver
Phase 1 Completed
NCT00181168 2018-11-02
Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Johns Hopkins University
Phase 2 Completed
NCT00604318 2013-01-10
Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
Copenhagen University Hospital at Herlev
Phase 4 Completed
NCT00435851 2007-02-19
Estimabl
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Unknown